Provided by Tiger Trade Technology Pte. Ltd.

Crescent Biopharma Inc

16.89
+0.12000.72%
Post-market: 16.84-0.0500-0.30%19:30 EDT
Volume:3.12M
Turnover:52.88M
Market Cap:627.36M
PE:-2.28
High:17.87
Open:16.67
Low:16.15
Close:16.77
52wk High:27.41
52wk Low:8.72
Shares:37.14M
Float Shares:15.95M
Volume Ratio:7.55
T/O Rate:19.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.4105
EPS(LYR):-12.8150
ROE:-160.75%
ROA:-69.15%
PB:8.65
PE(LYR):-1.32

Loading ...

May 15, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 05, 2023

Major Issues Report

8-K - Current report
Apr 07, 2023

Major Issues Report

8-K - Current report
Mar 30, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 30, 2023

Major Issues Report

8-K - Current report
Mar 21, 2023

Major Issues Report

8-K - Current report
Mar 02, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 19, 2023

Major Issues Report

8-K - Current report
Jan 05, 2023

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Dec 27, 2022

Major Issues Report

8-K - Current report
Dec 27, 2022

Business Combinations

425 - Prospectuses and communications, business combinations
Nov 14, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 04, 2022

Major Issues Report

8-K - Current report
Oct 07, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Sep 22, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 25, 2022

Major Issues Report

8-K - Current report
Aug 19, 2022

Major Issues Report

8-K - Current report